I own PSTI but rarely post anymore
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Capstone Turbine to Announce Third Quarter Fiscal Year 2014 Results on February 10, 2014
http://ih.advfn.com/p.php?pid=nmona&article=60804999&symbol=CPST
Sierra Wireless Extends Leadership in Key M2M Markets with Agreement to Acquire In Motion Technology
http://ih.advfn.com/p.php?pid=nmona&article=60802968&symbol=SWIR
Earnings Estimates Moving Higher for Pluristem Therapeutics (PSTI): Time to Buy?
Zacks
Pluristem Therapeutics, Inc. (PSTI), a bio-therapeutics company, could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on PSTI’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Pluristem Therapeutics could be a solid choice for investors.
Current Quarter Estimates for PSTI
Though there has been no upward or downward revision for Pluristem Therapeutics in the past 30 days, consensus estimate trend has been favorable for the company. Estimates have narrowed from a loss of 14 cents a share 30 days ago, to a loss of 13 cents today, a move of 7.1%.
Current Year Estimates for PSTI
Meanwhile, Pluristem Therapeutics’s current year figures are also looking quite promising. Though there has been no upward or downward revision for the company in the past month, consensus estimate trend has seen a boost for this time frame. Estimates have narrowed from a loss of 61 cents a share 30 days ago, to a loss of 54 cents today, a move of 11.5%.
Bottom Line
The stock has also started to move higher lately, adding 27.5% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future.
http://finance.yahoo.com/news/earnings-estimates-moving-higher-pluristem-112244429.html
$APNT - Not at .03 any more. Nice run over 3x and healthy pullback. Keep it on watch.
Pluristem CEO Zami Aberman to Present at Phacilitate Cell & Gene Therapy Forum 2014
"Zami Aberman, will make two presentations and speak in panel discussions at the 10th Annual Phacilitate Cell & Gene Therapy Forum. The conference will take place on January 27th through 29th, 2014 in Washington D.C."
http://ih.advfn.com/p.php?pid=nmona&article=60799016
Samsung licensed APNT patented tech. Now Google ($GOOG) has patent sharing with Samsung. How will this affect APNT? Google TV?
Also on Netflix is "The Monsters Inside Me". True stories that are scarier than any horror movie. Most episodes are on parasites so not sure NNVC could help.
http://animal.discovery.com/tv-shows/monsters-inside-me
VNTH - Interesting and anything that thin could run hard and fast but not sure about investing in the child company when it is the parent that has the NASA agreement? Also they still have to develop a working prototype? Will FDA approval be required?
If you have an interest in nano technology take a look at APNT and all the government research grants and the patents that they own. The new CEO has already shown that he can take a product to market so it could get real interesting with products for super efficient solar, bio-Ag, military body armor, golf clubs, hydrogen fuel tanks, thermal microprocessor cooling, etc
I also like NWBO NNVC and PSTI for long term.
I wonder if this is the start of an upgrade trend?
http://www.analystratings.net/stocks/NASDAQ/PSTI/
http://www.thelifesciencesreport.com/pub/co/5961#quote
Expert Comments:
Jason Kolbert, Maxim Group (1/21/14) "Pluristem Therapeutics Inc. is advancing placental expanded cells (PLX) on multiple fronts. In addition to the trial for muscle injury, we expect the company to see PLX enter the clinic this year in pre-eclampsia."
The Life Sciences Report Interview with Jason Kolbert (12/19/13) "I think a major paradigm shift is going to be led by those companies that have good balance sheets. . .it will also be led by companies that have partners with viable business models. Pluristem has a great partner in United Therapeutics Corp." More >
Eun Yang, Jefferies & Co. (11/21/13) "With partner CHA Bio & Diostech Ltd. primarily developing placental-derived adherent stromal cell (PLX-PAD), Pluristem Therapeutics Inc. is to focus on PLacental eXpanded (PLX) development in preeclampsia. Pending FDA approval of commercial-grade production of PLX (expected in January/February 2014), CHA Bio is to start phase 2/3 in critical limb ischemia and phase 2 in intermittent claudication in H1/14. In addition, Pluristem plans to start phase 1/2 in preeclampsia. Now we expect data from these studies in 2015. . .with ~$49M cash at the end of Q3/13 and ~$20M annual cash burn, Pluristem has enough cash for ~2 years."
George Zavoico, MLV & Co (11/5/13) "Yesterday, Pluristem Therapeutics Inc. announced positive results of a preclinical animal maternal and fetal toxicity study of its PLacental eXpanded (PLX) cells. . .as a fairly common unmet clinical need with potentially lethal outcomes, we think PLX cells for preeclampsia could be granted breakthrough therapy designation. These positive safety results could lead to the start of a clinical trial in H1/14 and marketing approval in 2017, in a bull case scenario. We reiterate our Buy recommendation and $4.50 one-year price target."
George Zavoico, MLV & Co (10/2/13) "Pluristem Therapeutics Inc. announced that the Israeli Ministry of Health approved the initiation of a phase 2 study of PLacental eXpanded cells for the treatment of intermittent claudication (IC). The approval is aligned with the company's previously announced strategy to conduct a multinational IC trial. . .we view the expansion of this trial into Israel as an effective strategy to accelerate patient enrollment."
MLV Capital Increases Pluristem Therapeutics Price Target to $6.00 (PSTI)
http://www.i3investor.com/servlets/fdnews/167984.jsp
Analysts at MLV Capital lifted their target price on shares of Pluristem Therapeutics (NASDAQ:PSTI) from $4.50 to $6.00 in a research report issued to clients and investors on Tuesday, American Banking News reports. The firm currently has a “buy” rating on the stock. MLV Capital’s target price would indicate a potential upside of 35.44% from the company’s current price.
Shares of Pluristem Therapeutics (NASDAQ:PSTI) traded down 4.51% during mid-day trading on Tuesday, hitting $4.23. The stock had a trading volume of 1,505,171 shares. Pluristem Therapeutics has a 1-year low of $2.47 and a 1-year high of $4.54. The stock’s 50-day moving average is $3.59 and its 200-day moving average is $3.31. The company’s market cap is $253.3 million.
In other Pluristem Therapeutics news, CFO Yaky Yanay sold 69,850 shares of the company’s stock on the open market in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $4.29, for a total transaction of $299,656.50. Following the sale, the chief financial officer now directly owns 1,069,616 shares of the company’s stock, valued at approximately $4,588,653. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Pluristem Therapeutics Inc (NASDAQ:PSTI) is a bio-therapeutics company engaged in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders.
Pluristem Gains Most in 17 Months on Stem-Cell Study Results
By David Wainer January 21, 2014
http://www.businessweek.com/news/2014-01-21/pluristem-gains-most-in-17-months-on-stem-cell-study-results
Pluristem Therapeutics Inc. (PSTI:US), the Israeli developer of stem-cell therapies, rose the most in more than 17 months after an experimental treatment showed promise in a study of 20 patients with muscle injuries.
The stock surged 22 percent to 16.18 shekels ($4.63) at 11:04 a.m. in Tel Aviv. Earlier it gained as much as 27 percent, the biggest increase since Aug. 6, 2012. The shares fell 15 percent yesterday ahead of the study results.
The early-stage clinical trial assessing Pluristem’s placental-expanded, or PLX-PAD, cells in people who had a buttock muscle injured during hip-replacement surgery found the treatment was safe, the company said in a statement today. Patients getting the injection also fared better in a muscle-contraction exercise six months later.
Rare Disease Linked to Dengue Virus Caused Texas Woman's Death
http://news.yahoo.com/rare-disease-linked-dengue-virus-caused-texas-woman-195857749.html
SENSIO Presents Its 2013-2014 Second Quarter Financial Results
http://ih.advfn.com/p.php?pid=nmona&article=60777661
$PSTI Pluristem's Cell Manufacturing Facility Marks Major Milestone With German Regulatory Approval of New Scaled-Up 3D Manufacturi...
http://ih.advfn.com/p.php?pid=nmona&article=60764223
ATMI to Report Results for the Fourth Quarter of 2013 on February 5, 2014
http://ih.advfn.com/p.php?pid=nmona&article=60752688&symbol=ATMI
Sierra Wireless to Report Fourth Quarter and Year End 2013 Results on February 5
http://ih.advfn.com/p.php?pid=nmona&article=60757129
Double post, may remove. eom
I don't know. Have not seen a proxy. I see great value here but after the great run-up and promotion, a pull back was expected and so far it has been a very low volume pull back. BWDIK
IDT Expands Industry-leading RF Signal Chain Portfolio With High-performance DPD Demodulator for Wireless Base Stations
http://ih.advfn.com/p.php?pid=nmona&article=60736550&symbol=IDTI
It is part of his CEO pay structure (got taxes?). He still owns 1.7 million shares. This is a thin stock (for NASDAQ) that has already had a run up into the announcement. The traders expecting a huge gap up on news are selling into the fear but I would not be surprised if this is close to a near-term bottom for the next level up, BWDIK.
IDT to Release Third Quarter Fiscal Year 2014 Financial Results on February 3, 2014
http://ih.advfn.com/p.php?pid=nmona&article=60697794
Ok, thanks for your input.
Why do all my stocks run at the same time? LOL Nice to see this NNVC breakout. I plan to tell my grandkids someday about when I was adding more NNVC before the reverse split and uplist! Been a long road and I don't post here much but it looks like blue sky ahead IMHO.
I like both companies but I do agree that the manufacturing edge that PSTI owns is of great value that has not been factored into the stock price. I consider this a safety net for the stock as I believe the stock is worth much more on just the manufacturing. If the clinical trials continue to progress with good results then sky is the limit. I also see this a possible play on potential problems from further meltdown and Fukushima radiation as the government is studying Pluristem stemcells as a possible radiation treatment. I sure hope this does not happen but I can see the government stockpiling just in case if they are pleased with their study.
BWDIK
Darrin Naughton, ICSF Cargo Security Manager at Mercury Air Cargo. "We are pleased to work with Implant Sciences, and have been impressed by their training, service, and support team."
I like what I see here but the main concern for the stock is the financing arrangements. It can be overcome with strong enough sales but it would be nice if they could rewrap the deals (and uplist) to make it clean and friendly to new investment. Should be some big money looking to take this onto the big board?
http://ih.advfn.com/p.php?pid=nmona&article=60655394
Applied Nanotech to change name after merger.
Austin Business Journal
http://www.bizjournals.com/austin/blog/techflash/2013/11/applied-nanotech-to-change-name-after.html
Actually it is the reverse.
OTC Dynamics is making people aware of stock promotions from different stock promoters.
“Penny Stock Prophet” is the one that has sent out a promotional on APNT.
But an important element to me is this statement:
"PennyStockProphet.com has not received any compensation for this profile coverage of Applied Nanotech Holdings Inc. APNT. PennyStockProphet.com does not own any shares of APNT."
So this is not a company promotion (companies often pay for promotion when insiders want to dump).
Easy nano, read it again. The link is to to the company that exposes promotions. So they appear to be a watchdog group.
Hey thanks for the heads up. To APNT's credit...
"PennyStockProphet.com has not received any compensation for this profile coverage of Applied Nanotech Holdings Inc"
I still like the company and have hope that the new Leadership can put all those valuable patent assets to work for us.
Chances are this promo will do a pump and dump before our new CEO has a chance to do anything IMHO.
iBio and Caliber Designate New Fusion Protein as Target Product Under License and Collaboration Agreement
http://ih.advfn.com/p.php?pid=nmona&article=60673651
Is this the same Ray Dirks?
http://www.siliconinvestor.com/subject.aspx?subjectid=52930
I had one experience with one of his stock promotions a couple years ago so I'm a little leery but that's just me. I've given my take and will not belabor the points.
For accuracy, I would first like to correct myself. The link I gave is not for the H.265 version. The same company does have three versions of their H.265 encoder but they all cost money to buy. However, I did find an open source and free x265.
If TMMI has a finished product (with audio and video in sync) then they should state the parameters of what can be expected for encoding speed, decoding speed on a given computer with the before and after file size. Better yet they could have it reviewed by someone who is trusted like this...
http://www.tomshardware.com/reviews/x265-hevc-encoder,3565.html
Or you can just go on blind faith and attack anyone who asks reasonable questions.
Well, they do not show even one product for sale on their website, so forgive my skepticism.
"All products are currently in development."
http://www.tmmi.us/?q=products
BTW I download and installed H.265 encoder for free and will play with it later when I have time.
http://download.cnet.com/Cinec/3000-2194_4-75843578.html